In conclusion, whereas both CIRP and RBM3 show common characteristics of proto-oncogenes at the cellular level, their roles in the clinical tumor setting are diverse, with CIRP as a marker of poor prognosis and RBM3 as a marker of good prognosis. The gene discussed is RBM3; the disease is neoplasm.